## SUPPLEMENTAL MATERIAL

## Lee et al., 10.1084/jem.20171389




Figure S1. Nonhealing infection with LmSd in C57BL/6 mice. Lesion development and pathology scores (0 = no ulceration, 1 = ulcer, 2 = half ear eroded, 3 = ear completely eroded) over the course of infection with  $10^3$  metacyclic LmFn and LmSd promastigotes in the ear dermis of C57BL/6 mice. Values represent mean  $\pm$  standard deviation (n = 5 mice per group).

JEM S21






Figure S2. **Phenotype analysis of P1–P4. (A and B)** Flow cytometric analysis of ear isolates from C57BL/6 animals at (A) 1 h after intradermal injection or (B) 2 h after intravenous injection of Manocept–Alexa Fluor 488–containing mannose moieties. PMN, polymorphonuclear leukocyte. Values represent mean  $\pm$  standard deviation (n = 4 ears per group). **(C)** In the top panels, the dermal populations of CD11b<sup>+</sup>Lin<sup>-</sup> cells were gated and defined as previously reported (Tamoutounour et al., 2013) as CD11b<sup>+</sup>Ly6C<sup>-</sup>CD64<sup>-</sup> dermal DCs (1), CD11b<sup>+</sup>CCR2<sup>lo</sup>CD64<sup>lo</sup>Ly6C<sup>lot</sup>MHCII<sup>-</sup> and MHCII<sup>+</sup> dermal macrophages (2 and 3), CD11b<sup>+</sup>CCR2<sup>lot</sup>CD64<sup>lo</sup>Ly6C<sup>lot</sup>MHCII<sup>-</sup> dermal monocytes (4), CD11b<sup>+</sup>CCR2<sup>lot</sup>CD64<sup>lo</sup>Ly6C<sup>lot</sup>MHCII<sup>lot</sup> dermal moDCs (5), and CD11b<sup>+</sup>CCR2<sup>lot</sup>CD64<sup>lot</sup>Ly6C<sup>lot</sup>MHCII<sup>lot</sup> dermal moDCs (6). In the bottom panels, the subsets 1–6 are overlaid on the P1–P4 gates. **(D)** Histograms showing M2 macrophage markers expressed on P1–P4 populations from naive ears.




Figure S3. **Effects of prolonged treatment of M279 antibodies in C57BL/6 mice. (A)** The serum concentration of M-CSF in animals treated with 200  $\mu$ g M279 or control lgG three times a week for 3 wk intraperitoneally. **(B)** Mean body weight changes of animals treated with 200  $\mu$ g M279 or control lgG three times a week for 6 wk intraperitoneally. **(C)** Flow cytometric analysis of peripheral blood mononuclear cells from mice treated with M279 three times a week for 3 wk. **(D)** MFIs of CSF-1R expression on P1-P4 from naive animals. Values represent mean  $\pm$  standard deviation (n = 4 mice per group). \*, P < 0.05; \*\*\*, P  $\leq$  0.001; \*\*\*\*, P  $\leq$  0.001 by nonparametric Mann-Whitney test (B).

JEM S23






Figure S4. **Th1 polarization in LmFn- and LmSd-infected C57BL/6 mice. (A)** The detection of antigen-specific T cell development (GPC 335–351 NDAFGVMPPVARLTPEQ) in ear lesions of mice infected with  $10^6$  metacyclic promastigotes at 8 d p.i. (**B and C**) The frequency of PMA/ionomycin-restimulated CD4<sup>+</sup> T and CD8<sup>+</sup> T cells in ear lesions (B) and dLNs stained positive for IFN- $\gamma$ , TNF- $\alpha$ , IL-2, and IL-10 at 8 d p.i. with  $10^6$  metacyclic promastigotes (C). Values represent mean  $\pm$  standard deviation (n = 4 mice per group). \*, P < 0.05 by nonparametric Mann-Whitney test (B and C).




Figure S5. **IL-13** is not required to maintain the P4 dermal macrophages in LmSd-infected mice. (A) The frequency of P1-P4 populations in naive C57BL/6,  $il4^{-/-}$ ,  $il10^{-/-}$  mice. ko, knockout. (B) Representative plots (left) showing the frequency of polymorphonuclear leukocytes (PMNs), eosinophils, and P1-P4 populations in C57BL/6 and  $il13^{-/-}$  mice at day 12 p.i. with 2 × 10<sup>5</sup> LmSd. Bar graphs show the frequency and absolute number of these populations. Values represent mean  $\pm$  standard deviation (n = 5 mice per group). \*, P < 0.05 by nonparametric Mann-Whitney test (B).

## **REFERENCE**

Tamoutounour, S., M. Guilliams, F. Montanana Sanchis, H. Liu, D. Terhorst, C. Malosse, E. Pollet, L. Ardouin, H. Luche, C. Sanchez, et al. 2013. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. *Immunity.* 39:925–938. https://doi.org/10.1016/j.immuni.2013.10.004

JEM S25